Floatz logo

Humanized Cd19 Car-T Cells

Non-hodgkin Lymphoma,B Cell

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

316 Active assets in the Non-hodgkin Lymphoma,B Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Humanized Cd19 Car-T Cells is also rated in:

B-cell acute lymphoblastic leukemiaDormant
C
Indicative ·
39 / 100
View asset →
acute lymphoblastic leukemiaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →